Phase II study of the thymidylate synthetase inhibitor CB3717 (N'0-propargyl-5, 8-dideazafolic acid) in colorectal cancer
1988
Study of CB3717 in Colorectal Cancer
Sample size: 26
publication
Evidence: low
Author Information
Author(s): M.J. Harding, B.M.J. Cantwell, R.A.V. Milstead, A.L. Harris, S.B. Kaye
Primary Institution: University of Glasgow and University of Newcastle-upon-Tyne
Hypothesis
Is CB3717 effective in treating colorectal cancer?
Conclusion
CB3717 is unlikely to be active in human colorectal cancer.
Supporting Evidence
- Two of four patients with colon cancers showed a minor tumour response during phase I.
- Seventy-five cycles of CB3717 were administered with a median of 3 cycles per patient.
- Seven patients had disease stabilization for 3-10 months.
Takeaway
The study tested a new drug called CB3717 on patients with colorectal cancer, but it didn't work well.
Methodology
Patients with advanced colorectal cancer were treated with CB3717, and their responses were evaluated after three courses of treatment.
Limitations
Prior therapy with standard antifol drugs may have affected the outcomes.
Participant Demographics
26 patients, 14 male and 12 female, median age 58 years.
Want to read the original?
Access the complete publication on the publisher's website